Skip to main content
Home > The Daily Extra > Company News

Chronological Index of : Company News

 Current Issue
  • COMPANY NEWS: BioMarin completes NDA submission for drisapersen

    BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) completed the submission of a rolling NDA to FDA for drisapersen (PRO051) to treat a genetically defined subset of patients with Duchenne muscular dystrophy (DMD).Drisapersen, …

    Published on 4/27/2015
  • COMPANY NEWS: Celgene exercises option to acquire Quanticel

    Celgene Corp. (NASDAQ:CELG) exercised its option to acquire Quanticel Pharmaceuticals Inc. (San Francisco, Calif.) for $100 million up front. Celgene gains Quanticel's platform to perform single-cell genomic analysis of…

    Published on 4/27/2015
  • COMPANY NEWS: Hepalink gains rights to Resverlogix's RVX-208 in China

    Shenzhen Hepalink Pharmaceutical Co. Ltd. (Shenzhen, China) gained exclusive development and commercialization rights to RVX-208 from Resverlogix Corp. (TSX:RVX) in greater China.Resverlogix President and CEO Donald …

    Published on 4/27/2015
  • COMPANY NEWS: Management tracks

    Diagnostics company Invitae Corp. (NYSE:NVTA) named Robert Nussbaum CMO, effective Aug. 1. Nussbaum was chief of the division of genomic medicine at the University of California San Francisco Medical Center; he will …

    Published on 4/27/2015
  • COMPANY NEWS: M&A roundup: Teva/Mylan, Aerocrine, Swedish Orphan

    The board of Mylan N.V. (NASDAQ:MYL) unanimously rejected an unsolicited bid from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to acquire the company for $82 per share, or $40.1 billion in cash and stock. Mylan said …

    Published on 4/27/2015
  • COMPANY NEWS: Roche, 4D to develop AAV vectors

    Roche (SIX:ROG; OTCQX:RHHBY) partnered with 4D Molecular Therapeutics LLC (San Francisco, Calif.) to use 4D's Directed Vector Evolution platform to develop next-generation adeno-associated viral (AAV) vectors. 4D co-…

    Published on 4/27/2015
  • COMPANY NEWS: AZ licenses NKG2A inhibitor from Innate Pharma

    Innate Pharma SA (Euronext:IPH) gained EUR 4.38 (49%) to EUR 13.35 after the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) paid $250 million up front for rights to Innate's IPH 2201 to treat cancer.The deal …

    Published on 4/24/2015
  • COMPANY NEWS: Celgene pays $450M to share MEDI4736 with AZ

    Celgene Corp. (NASDAQ:CELG) and the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) entered an exclusive collaboration agreement to develop AZ's MEDI4736, a human IgG1 mAb targeting PD-L1 to treat blood …

    Published on 4/24/2015
  • COMPANY NEWS: CHMP backs Opdivo and Hetlioz, spurns Lympreva

    EMA's CHMP issued several recommendations on Friday, backing marketing authorization of candidates from Bristol-Myers Squibb Co. (NYSE:BMY) and Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) while declining to recommend one …

    Published on 4/24/2015
  • COMPANY NEWS: FDA adds mCRC to Lilly's Cyramza label

    FDA approved an sBLA from Eli Lilly and Co. (NYSE:LLY) for Cyramza ramucirumab in combination with FOLFIRI chemotherapy to treat metastatic colorectal cancer patients who have progressed on first-line therapies …

    Published on 4/24/2015
  • COMPANY NEWS: ImmunoGen regains rights to DLBCL candidate

    ImmunoGen Inc. (NASDAQ:IMGN) said it regained rights to coltuximab ravtansine (SAR3419) from Sanofi (Euronext:SAN; NYSE:SNY). The humanized CD19 mAb linked to ImmunoGen's DM4 cytotoxic agent met the primary endpoint …

    Published on 4/24/2015
  • COMPANY NEWS: AbbVie maintains Viekira Pak forecast

    AbbVie Inc. (NYSE:ABBV) reported $231 million in global 1Q15 sales of HCV regimen Viekira Pak paritaprevir/ritonavir/ombitasvir/dasabuvir and maintained its forecast of a global annualized sales run rate of more than $3…

    Published on 4/23/2015
  • COMPANY NEWS: Bass keeps fishing for patent challenges

    Continuing a string of patent challenges, hedge fund manager Kyle Bass filed an inter partes review (IPR) challenging a patent held by Celgene Corp. (NASDAQ:CELG) covering Revlimid lenalidomide. Celgene markets the …

    Published on 4/23/2015
  • COMPANY NEWS: Management tracks

    Royalty play Ligand Pharmaceuticals Inc. (NASDAQ:LGND) said CFO Nishan de Silva resigned effective May 20. Melanie Herman, Ligand's director of accounting and chief accounting officer, will be interim CFO.Renal …

    Published on 4/23/2015
  • COMPANY NEWS: MedImmune, Juno to test PD-L1/CAR T combo

    Juno Therapeutics Inc. (NASDAQ:JUNO) and the MedImmune LLC unit of AstraZeneca plc (LSE:AZN; NYSE:AZN) entered a non-exclusive collaboration to study a combination of MedImmune's PD-L1 inhibitor MEDI4736 and a Juno …

    Published on 4/23/2015
  • COMPANY NEWS: Novartis hunting for $2-$5B acquisitions

    After closing its $16 billion asset swap with GlaxoSmithKline plc (LSE:GSK; NYSE:GSK), Novartis AG (NYSE:NVS; SIX:NOVN) said on its 1Q15 earnings call Thursday that it is seeking bolt-on acquisitions on the order of $2…

    Published on 4/23/2015
  • COMPANY NEWS: NYU, MRC Tech in antibody deal for osteolysis

    U.K.-based not-for-profit MRC Technology partnered with New York University School of Medicine to develop antibodies against the university's targets to treat inflammatory osteolysis, a disease involving breakdown and …

    Published on 4/23/2015
  • COMPANY NEWS: Astellas partners with Potenza, takes equity stake

    Astellas Pharma Inc. (Tokyo:4503) partnered with Potenza Therapeutics Inc. (Cambridge, Mass.) to develop the biotech's preclinical immuno-oncology candidates.Astellas made an undisclosed equity investment in Potenza and…

    Published on 4/22/2015
  • COMPANY NEWS: Management tracks

    Gene editing company Intellia Therapeutics LLC (Cambridge, Mass.) named Sapna Srivastava as chief financial and strategy officer. Srivastava was a senior analyst at Goldman Sachs.Cancer therapeutics play Aveo …

    Published on 4/22/2015
  • COMPANY NEWS: Novo launches Saxenda in the U.S.

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO) announced the U.S. launch of weight loss drug Saxenda liraglutide. Novo spokesperson Ken Inchausti said the drug's list price is $1,068/month. FDA approved Saxenda in December for …

    Published on 4/22/2015
  • COMPANY NEWS: Roche gives timeline for its anti-PD-L1

    Roche (SIX:ROG; OTCQX:RHHBY) reported 1Q15 earnings Wednesday and discussed clinical and regulatory plans for its anti-PD-L1 candidate MPDL3280A. The company said it plans to submit a regulatory application in 2016 for …

    Published on 4/22/2015
  • COMPANY NEWS: Tecfidera becomes latest Bass target

    Multiple sclerosis (MS) drug Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB) is the newest target in a string of patent challenges from hedge fund manager Kyle Bass.Coalition for Affordable Drugs V, an entity…

    Published on 4/22/2015
  • COMPANY NEWS: Actelion gains after boosting guidance

    Actelion Ltd. (SIX:ATLN) gained CHF6.10 to CHF123 on Tuesday after reporting earnings and raising its 2015 guidance. The company now expects core earnings growth in the low double digits, at constant exchange rates and …

    Published on 4/21/2015
  • COMPANY NEWS: Bass now targeting Imbruvica patent

    Pharmacyclics Inc. (NASDAQ:PCYC) became the latest company to face a patent challenge from hedge fund manager Kyle Bass, joining Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Shire plc (LSE:SHP; NASDAQ:SHPG) and Acorda …

    Published on 4/21/2015
  • COMPANY NEWS: Management tracks

    Advisory firm Avalere Health (Washington, D.C.) said Tanisha Carino, EVP of its life sciences unit, will leave the company to lead U.S. public policy at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK). Avalere named Nancy McGee…

    Published on 4/21/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993